Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
| ▸ | GRK5 | P34947 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23022319 | 0.87 | FGFR1 (0.30) | KDM4CKDM4EKDM4AKDM5CKDM4D | |
| SCHEMBL23022280 | 0.84 | — | — | |
| SCHEMBL23022279 | 0.83 | JAK1 (0.39) | JAK1KDM4CKDM4EKDM4AKDM5C | |
| SCHEMBL23022183 | 0.81 | MET (0.36) | KDM4CKDM4EKDM4AKDM5CKDM4D | |
| SCHEMBL23022232 | 0.81 | MET (0.41) | KDM4CKDM4EKDM4AKDM5CKDM4D | |
| SCHEMBL24269833 | 0.79 | — | — | |
| SCHEMBL26686079 | 0.78 | MAP3K12 (0.34) | KDM4CKDM4EKDM4AKDM5CKDM4D | |
| SCHEMBL26686074 | 0.78 | MAP3K12 (0.34) | KDM4CKDM4EKDM4AKDM5CKDM4D | |
| SCHEMBL29548344 | 0.78 | MAP3K12 (0.34) | KDM4CKDM4EKDM4AKDM5CKDM4D | |
| SCHEMBL24270064 | 0.77 | MAP4K3 (0.44) | GRK5MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114341127-B | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-09-15 | — | — | US | disclosed |
| CN-114341127-A | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | MAPKAPK5, STK25, STK35 | JAK1 1075/4885PIK3R1 1806/4885PIK3CA 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.